# US 2008/0187556 A1 · Medicine for Treating Tumor and Use Therefor in Preparation of the Medicaments for Treating Tumor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187556 A1
- Document ID: US20080187556A1
- Status: Published application
- Kind: A1
- Application number: 12/042,367
- Filed: 2008-03-05
- Published: 2008-08-07
- Earliest claimed: 2005-09-16
- Inventors: Jieguang SUN; Xueran SUN
- Web page: https://patentgrep.com/patent/US20080187556A1

## CPC

- A61K 39/205: Rhabdoviridae, e.g. rabies virus
- A61K 39/12: Viral antigens
- A61P 35/00: Antineoplastic agents
- A61K 35/13: Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00)
- A61K 2039/585: {wherein the target is cancer}
- C12N 2760/20134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2810/6081: rhabdoviridae, e.g. VSV
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein is a medicine comprising an active component of Rabies Vaccine for Human Use and methods of using thereof to treat tumors and HPV infections. The compositions and methods did not result in any observable side-effects in the experiments disclosed herein and were observed to adjust body function and improve cell and body fluid immunity. Animal experiments disclosed herein exhibit that the compositions and methods provide anti-oxidative and anti-aging effects. The methods and compositions prevent or inhibit cellular damage and enhance immunity and cellular function and repair.

## Claims

### Claim 1

A pharmaceutical composition comprising a rabies vaccine or a rabies serum immune globulin as an active ingredient.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the rabies vaccine is approved for human use.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the rabies vaccine is made with vero cells, renal cells, shrewmouse embryos, hamsler embryos, or chick embryos.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the virus used to make the rabies vaccine was Pasteur PM, PV, CTN, or AG.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the rabies vaccine is a liquid or a freeze dried powder.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, and further comprising a chemotherapeutic agent.

### Claim 7 (depends on 1)

A method for treating a tumor in a subject which comprises administering the pharmaceutical composition of claim 1 to the subject.

### Claim 8 (depends on 7)

The method of claim 7, which further comprises administering a chemotherapeutic agent to the subject.

### Claim 9 (depends on 7)

The method of claim 7, wherein about 2.5 IU to about 10 IU of the rabies vaccine is administered per dosage or per day.

### Claim 10 (depends on 7)

The method of claim 7, wherein the subject is treated for about 20 to about 30 days.

### Claim 11 (depends on 7)

The method of claim 7, wherein the composition is administered more than once at intervals of 1 to 7 days.

### Claim 12 (depends on 8)

The method of claim 8, wherein the chemotherapeutic agent is administered at about 2.5 IU to about 10 IU per dosage or per day.

### Claim 13 (depends on 8)

The method of claim 8, wherein the chemotherapeutic agent is IFN, Thymosin Alpha-1, IL-2, TA, immune RNA and cytokine, or a combination thereof.

### Claim 14 (depends on 7)

The method of claim 7, wherein the composition is administered intramuscularly.

### Claim 15 (depends on 7)

The method of claim 7, wherein the composition is administered as a topical spray.

### Claim 16 (depends on 15)

The method of claim 15, wherein about 0.15 IU to about 11 IU is administered per dosage or per day.

### Claim 17 (depends on 15)

The method of claim 15, wherein the composition comprises about 0.5 IU of the rabies vaccine in about 0.75 to about 5.0 ml diluent.

### Claim 18 (depends on 15)

The method of claim 15, wherein the subject is administered the composition once per day for about 20 to about 30 days.

### Claim 19 (depends on 15)

The method of claim 15, and further comprising administering about 2.5 IU to about 10 IU of a chemotherapeutic agent per dosage or per day.

### Claim 20 (depends on 19)

The method of claim 19, wherein the chemotherapeutic is IFN, Thymosin Alpha-1, IL-2, TA, immune RNA and cytokine, or a combination thereof.

### Claim 21 (depends on 7)

The method of claim 7, wherein the tumor is caused by a human papilloma virus.

### Claim 22 (depends on 1)

A method of treating an infection caused by a human papilloma virus in a subject which comprises administering to the subject the pharmaceutical composition of claim 1.